// App-Quantinova.ai

2955 : Herceptarg, a novel heterodimeric biparatopic common light chain IgG1 antibody based on trastuzumab and pertuzumab, exerts potent anti-tumoral activity

Researchers

Presenter

  • Ekkehard Moessner

Principal Investigators

  • Thomas Hofer

  • Inja Waldhauer

  • Werner Scheuer

  • Ralf Hosse

  • Lydia Duerner

  • Mi He

  • Karlheinz Zick

  • Jens Fischer

  • Claudio Sustmann

  • Tina Weinzierl

  • Marina Bacac

  • Christian Gerdes

  • Pablo Umana

  • Christian Klein

Medical Centers

  • Roche Pharma Research & Early Development, Basel, Switzerland

  • Roche Pharmaceutical Research & Early Development, Penzberg, Germany

Locations

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Kawasaki disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

  • Pertuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved